[{"id":"f0d60d32-5a07-4a7a-b554-6e1f44909e29","acronym":"","url":"https://clinicaltrials.gov/study/NCT04340167","created_at":"2021-01-18T21:00:26.976Z","updated_at":"2024-07-02T16:36:05.527Z","phase":"Phase 2","brief_title":"Study of Anti-CD22 CAR-T Cells Treating Leukemia Children","source_id_and_acronym":"NCT04340167","lead_sponsor":"Beijing Boren Hospital","biomarkers":" ABL1 • CD22","pipe":" | ","alterations":" CD22 positive • CD22 expression","tags":["ABL1 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Anti-CD22 CAR-T Cells"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/01/2020","start_date":" 05/01/2020","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2022-08-15"}]